### 16th Finance Commission of India

**Overview**
*   **Constitution:** Formed under **Article 280** of the Indian Constitution.
*   **Purpose:** To provide recommendations on the distribution of net proceeds of taxes between the Union and the States (Vertical Devolution) and among States (Horizontal Devolution).
*   **Period:** Recommendations will cover a five-year period starting from **April 1, 2026**.
*   **Deadline:** The Commission is requested to make its report available by **October 31, 2025**.

**Key Appointments**
| Position | Name | Background |
| :--- | :--- | :--- |
| **Chairman** | Arvind Panagariya | Former Vice-Chairman of NITI Aayog |
| **Secretary** | Ritvik Ranjanam Pandey | IAS Officer |
| **Full-time Member** | Ajay Narayan Jha | Former member of 15th FC |
| **Full-time Member** | Annie George Mathew | Former Special Secretary (Expenditure) |
| **Full-time Member** | Niranjan Rajadhyaksha | Executive Director, Artha India |
| **Part-time Member** | Soumya Kanti Ghosh | Group Chief Economic Advisor, SBI |

**Terms of Reference (ToR)**
*   **Distribution of Taxes:** Allocation of the share of central taxes among states.
*   **Grants-in-aid:** Principles governing the grants-in-aid of the revenues of the States out of the Consolidated Fund of India.
*   **Panchayats and Municipalities:** Measures needed to augment the Consolidated Fund of a State to supplement the resources of local bodies.
*   **Disaster Management:** Reviewing the present arrangements for financing Disaster Management initiatives with reference to the funds constituted under the Disaster Management Act, 2005.

---

### India’s First Homegrown Gene Therapy for Cancer (NexCAR19)

**Technical Details**
*   **Type:** CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy).
*   **Development:** Developed by **ImmunoAdoptive Cell Therapy (ImmunoACT)**, an IIT Bombay-incubated company, in collaboration with Tata Memorial Hospital.
*   **Mechanism:**
    1.  T-cells (immune cells) are extracted from the patient's blood.
    2.  Genetically modified in a lab to express specific proteins (CARs) on their surface.
    3.  Modified cells are re-infused into the patient to target and kill cancer cells.

**Key Features**
*   **Target:** Specifically targets **B-cell malignancies** (Leukemia and Lymphoma).
*   **Approval:** Received market authorization from the Central Drugs Standard Control Organization (CDSCO) in late 2023.
*   **Cost Efficiency:** Estimated to cost **₹30–40 lakh**, significantly lower than international treatments (which can exceed ₹3–4 crore).

---

### Project Akashdeep (Indigenous Surface-to-Air Missile System)

**Project Specifications**
*   **Objective:** To enhance the Indian Army’s air defense capabilities through indigenous technology.
*   **System Name:** **Akash Weapon System**.
*   **Range:** Short-range Surface-to-Air Missile (SAM) capable of engaging targets up to **25 km**.

**Deployment and Infrastructure**
*   **Integration:** Integration of radar and communication systems to provide a multi-layered defensive shield.
*   **Command and Control:** Features automated firing and tracking systems to engage multiple aerial targets simultaneously (drones, fighter jets, helicopters).
*   **Indigenization:** Part of the "Atmanirbhar Bharat" initiative to reduce reliance on imported defense systems like the Russian S-400.